New Delhi: US-based vaccine developer, Modern announced its Phase 3 trial data COVID-19/Influenza Combination VaccinemRNA-1083. Data shows the vaccine has the potential to combat it infectious diseaseAccording to data analytics company GlobalData.

In the study, the investigational combination mRNA vaccine produced statistically higher immune responses than the licensed comparator vaccines used in a randomized, observer-blind, active control study among 8,000 adults aged 50 years and older.

In trials, Moderna reported that a single dose of mRNA-1083 met immunogenicity non-inferiority criteria compared to licensed comparator vaccines: Fluzone High Dose and Fluarix for influenza, and SpikeVax for COVID-19, and generated high immune responses against influenza strains including H1N1, H3N2, and B/Victoria, as well as SARS-CoV-2. The investigational combination vaccine demonstrated an acceptable safety and tolerability profile, with the most commonly reported adverse reactions being injection site pain, fatigue, myalgia, and headache.

This development comes less than two weeks after Moderna’s FDA approved the first mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA, further demonstrating its potential. mRNA Technology In fighting infectious diseases.

Commenting on this, Stephanie Kurdach, infectious disease analyst at GlobalData, said, “The development of a COVID-19/influenza combination vaccine could be beneficial for patients, as it would reduce the number of injections needed to provide adequate protection against many respiratory diseases. The development of a combination vaccine is strategic for pharmaceutical companies, as successful use of the vaccine could translate into significant market share under multiple indications.”

“If approved, Moderna’s COVID-19/influenza combination vaccine will be a significant addition to the vaccine market. Positive aspects Phase III data “This further reinforces how mRNA technology is advancing the treatment of infectious diseases,” Kurdach said.

Many experts have expressed positive opinions on the development of the COVID-19/influenza combination vaccine, as well as the advancement of vaccines for infectious diseases due to mRNA technology, as mRNA vaccines take less time to produce, have the ability to include a larger number of antigens, and may therefore be more effective than traditional vaccines.